Search Results 321-330 of 18600 for alzheimers
Polymorphism of the APOE gene is a major genetic determinant of late-onset Alzheimer's disease (AD). APOE4 confers up to a fifteen-fold greater risk of ...
Forgetfulness and memory loss are trademark symptoms of Alzheimer's disease. Personality changes are also somewhat common. Dr. Ronald Petersen, a Mayo Clinic ...
The trial used Eli Lilly's drug solanezumab, an antibody, to try to target the building blocks of amyloid plaques in the brains of the those with Alzheimer's.
It's estimated that 5 million Americans age 65 and older may have Alzheimer's disease. And with an aging population on the rise, that number is expected to ...
Genome-wide association studies of late-onset Alzheimer's disease (LOAD) have identified many risk variants. The lab has assessed the association of the top ...
A Study Evaluating the Use of 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease ... Alzheimer's Disease (EOAD) using a 48-hour CAA-EEG.
About this study. McLean hospital, Mayo Clinic, Emory University, LIJ/Northwell, and Pine Rest Mental Health are conducting a research study ...
"Screening for the sleep disorder in a patient with dementia could help clinicians diagnose either dementia with Lewy bodies or Alzheimer's disease," she says.
It was 33 years ago that President Ronald Reagan launched the first national Alzheimer's disease awareness campaign. Since then, research has developed ways ...
Eugenia Trushina, Ph.D., is leading basic science research that could someday lead to solutions for people with Alzheimer's. Targeting mitochondria is a ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.